Document is current

Article History

Received: 13 February 2023

Accepted: 23 June 2023

First Online: 25 July 2023

Declarations

:

: Not applicable.

: Not applicable.

: NS has received research grant funding from Olatec and consulting fees from Horizon Therapeutics, Alnylam Pharmaceuticals, JW Pharmaceutical Corporation, LG chem, Sobi, Protalix and Novartis. MHP has served as a consultant to Swedish Orphan Biovitrum, Horizon Therapeutics, and Fortress Biotech and holds investigator-initiated grants for unrelated investigations from Hikma Pharmaceuticals and Horizon Therapeutics. LSS has financial relationships with Abbott, Abraxxis, AcelRx, Affinergy, Agenus, Alpha Rx, Alder, Alimera, Altea, Analgesic Solutions, Antares, Anthera, Array, Asahi, AstraZeneca, Avanir, Bayer, CaloSyn, Cephalon, Cerimon, Daiichi Sankyo, Dara, Dr. Reddy’s, DURECT, Eicos Sciences, Eli Lilly and Company, EMD Serono, Eupraxia, Extera, Fidelity, Flexion, Forest, Genco, Genzyme, Gilead, Hisamatsu, Horizon, Idera, Imprimis, Inmedix, Inotek, Jazz, JP Morgan, JRX Biopharm, Kiniksa, Knopp, Kowa, Leerink Swann, Luxor, Medac, Metabolex, Neos, Nomura, Novartis, NuvoResearch, Omeros, Parexel, Pfizer, PLx Pharma, Pozen, Proprius, pSivida, Purdue, Regeneron, Remedy, Rigel, Roche, Sammuded, Sandoz, Sanofi, Shire, Takeda, Talagen, Teva, TiGenix, Vical, Wyeth and XTL. PEL is an employee of AMPEL BioSolutions and has received consultant fees from Horizon Therapeutics.